IBMS 2023
IBMS 2023
Biochemistry Stand #301
Join us at stands #301 each day of IBMS 2023 where will be hosting a range of interactive and educational workshops.
10:00-10:30: Workshop 1 / Acusera 24.7; The worlds most advanced statistical analysis software
11:15-11:45: Workshop 2 / Introducing Third Party Xanthochromia IQC
12:30-13:00: Workshop 3 / Importance of using Serum Indices IQC
14:00-14:30: Workshop 4 / Introducing Third Party Pre-Eclampsia IQC
15:15-15:45: Workshop 5 / Acusera 24.7; The worlds most advanced statistical analysis software
Click the link below to attend!
Meet the Team
Click on the team member’s photo to request a meeting
Barry Maguire
UK Sales Manager
Dipesh Varu
Regional Sales Manager
Dermot Devlin
Business Development, Scotland & Wales
Veena Vara
Sales Executive, North West England
Molecular Stand #302
Randox Molecular Solutions
Join us at stands #302 to discover the full range of Randox Molecular Diagnostic Solutions.
Designed to meet the demand’s of today’s molecular diagnostic laboratory, the Randox range of molecular products comprises; IQC and EQA for molecular infectious disease testing as well as Point of Care, semi and fully automated analysers. Stop by our booth and discuss Qnostics, QCMD, The Vivalytic, The Discovery and more with our team of specialists.
Meet the Team
Click on the team member’s photo to request a meeting
Ben Crawford
Molecular Products, Manager
Harpreet Singh
Molecular Product Specialist
Craig Ryan
Molecular Product Specialist
Our Portfolio
Dedicated to Improving Health Worldwide
With over four decades of experience in the medical diagnostics industry, Randox is dedicated to enhancing global health outcomes. As a provider of high-quality diagnostic solutions, Randox offers a wide range of products and services, including Quality Control, Molecular Diagnostics, Third Party Reagents, Point of Care, and Clinical Chemistry Analysers.
Acusera Quality Controls
Introducing the New Acusera True Third Party Controls. Book a meeting with a Randox QC Specialist today to learn how we can provide you with complete QC solutions for results you can trust.
Molecular Diagnostics at the Point of Care
The all in one molecular solution developed by Bosch and Randox consolidates full molecular workflow into one small benchtop platform. Randox multiplex Biochip Technology powers the Vivalytic enabling multiple results from one patient sample. Click the link below to learn more about the Vivalytic.
ACUSERA 24•7 Interlaboratory Data Management
Discover features such as; Interactive Levey-Jennings Charts, Automatic Calculation for uncertainty of Measurement as well as the Comprehensive Reports generated on demand, with a live demonstration at EuroMedLab.
RIQAS
The world’s largest External Quality Assessment Scheme with more than 55,000 laboratory participants spanning over 134 countries. Choice and flexibility are guaranteed with our 36 programme portfolio, learn more by clicking the button below!
AACC 2023
We will be exhibiting at 2023 AACC!
We invite you to stop by the Anaheim Convention Center between July 25 and July 27, 2023 for a visit.
With over four decades of experience in the medical diagnostics industry, Randox is dedicated to enhancing global health outcomes. As a provider of high-quality diagnostic solutions, Randox offers a wide range of products and services, including Quality Control, Molecular Diagnostics, Third Party Reagents, Point of Care, and Clinical Chemistry Analysers.
Meet The Team
If you plan to attend 2023 AACC, our Product Specialists Team will be available at Booth #3223 to answer any questions you may have. To ensure the most productive use of your time, we recommend scheduling a meeting with one of our Randox representatives in advance to discuss your specific needs and book a time slot during the event by clicking on the button below:
WorldLab – EuroMedLab 2023
Join us at the Randox booth for EuroMedLab 2023!
Booth #153
Visit us at booth #153 La Nuvola – Roma Convention Centre from 22nd May-25th May 2023.
With 40 years of experience in the industry, we are experts in the field. Our team of Product Specialists will be available at booth #153 to answer any questions, but why not plan ahead? Request a meeting with a Randox representatives and secure a time slot across the 4 day event.
Our Extensive Product Range
Acusera Quality Controls
Introducing the New Acusera True Third Party Controls. Book a meeting with a Randox QC Specialist today to learn how we can provide you with complete QC solutions for results you can trust
Vivalytic – Molecular Diagnostics at the Point of Care
The all in one molecular solution developed by Bosch and Randox consolidates full molecular workflow into one small benchtop platform. Randox multiplex Biochip Technology powers the Vivalytic enabling multiple results from one patient sample. If you would like to learn more about the Vivalytic, click the link below.
ACUSERA 24•7 Interlaboratory Data Management
Discover features such as; Interactive Levey-Jennings Charts, Automatic Calculation for uncertainty of Measurement as well as the Comprehensive Reports generated on demand, with a live demonstration at EuroMedLab.
RIQAS
The world’s largest External Quality Assessment Scheme with more than 55,000 laboratory participants spanning over 134 countries. Choice and flexibility are guaranteed with our 36 programme portfolio, learn more by clicking the button below!
EuroMedLab Meeting Request
Randox Covid-19 Testing: Evaluating the health, social and economic impacts
3rd April 2023: COVID-19 Report Reveals How Randox’s 25 Million PCR Tests Averted Thousands of Hospitalisations and Deaths And Delivered Billions of Pounds Of Economic Benefits
A new report on the work of leading diagnostics company Randox shows that its COVID-19 PCR testing in the public and private sectors averted more than 3,000 UK deaths and 14,100 additional hospitalisations during the pandemic emergency.
That assessment is contained in an evidence-based report into the performance and delivery of Randox during the crisis, compiled by internationally respected economic development consultants OCO Global.
As well as illustrating the impact of PCR testing on deaths and hospitalisations, the report provides an assessment of the wider economic benefit of the test and trace programme.
It reveals that Randox testing delivered £8.3 billion of benefits to the UK economy, by reducing transmission and expediting the return to work for key workers, as well as facilitating social engagement and international travel, crucial to economic recovery.
The report is believed to be one of the most comprehensive analyses of any company awarded government Covid-19 contracts. It will also be provided to the COVID-19 Public Inquiry to assist their considerations regarding future evidence that may be required.
In total, the OCO Global report confirms that Randox processed over 17 million PCR tests as part of the government’s national testing programme between March 2020 and June 2022. The company also provided a further 7.7 million PCR tests plus around 1.8 million lateral flow tests to corporate clients and international travelers.
The report estimates that Randox’s private testing facilitated 4.4 million international return journeys, many of them crucial to support the economy in a time of medical and financial emergency. Other tests supported the nation’s social fabric, enabling people to travel for leisure purposes and to meet families.
The evidence highlights the Northern Ireland-based company’s 40 years experience as one of the world’s leading diagnostic testing companies. This experience, says the OCO report, coupled with the company’s ability and willingness as a private business to innovate and invest its own resources in rapidly upscaling to meet the crisis enabled it successfully to deliver testing on a vast scale. The report also says that innovation in software, automation and robotics, in particular, helped ensure that Randox optimised laboratory efficiency and drove down costs to the benefit of contracting parties.
The report sets out the high level of financial risk taken by Randox during the pandemic and their rapid expansion of laboratories, staff levels and capacity to meet the emergency demand for testing.
In just ten months, Randox increased its capacity to process PCR tests – from 300 tests per day on March 30th 2020, to 120,000 per day by January 2021.
This involved building, equipping and staffing 80,000 square feet of PCR testing laboratory space at the Randox Science Park in County Antrim – the equivalent of a football pitch of new laboratory space.
Overall, the report confirms these improvements and development enabled Randox to deliver 12 per cent of the UK’s PCR testing – and a considerably higher percentage at times when Covid-19 cases, hospitalisations and deaths rocketed to their highest levels. It also notes that the Randox rate of void samples was 15 per cent below the average for the testing programme as a whole.
The report adds: “These improvements would be passed on to the UK Treasury as Randox was able to drive down the cost of testing from £49.60 to £18.00.
“Private individuals also benefited from Randox process improvement as the company was at the forefront of driving down the price of private testing. By October 2021 the cost of a PCR test (click and collect) would be £34.99, a 70 percent decrease from December 2020.” This price included the sample collection kits and all logistics and services, not within the government contracts.
In assessing Randox’s performance the report goes on to say: “Randox is a privately owned company that can make decisions quickly and this proved invaluable in the frenetic early stages of the pandemic when companies and governments across the world were scrambling for supplies and consumables.
“Randox’s willingness to invest came with significant risk: through the majority of the National Testing Programme, Randox were only paid for tests completed and there were no guarantees that payment for the number of tests indicatively contracted for would be received.
“This placed considerable risk with Randox who were having to purchase vast quantities of consumables, despite the uncertainty around how long the pandemic would last or how government policy might change.
“It was this successful risk management which enabled Randox to be one of the best performing laboratories across the National Testing Programme.”
Gareth Hagan, CEO of OCO Global said:
“OCO Global was commissioned by Randox to compile a full, open and comprehensive report into the value of the company’s work, performance and delivery of PCR testing during the pandemic. Randox was a cooperative partner, providing access both to data and to personnel from across the organisation.
“We were able to use external interviews and data sources to corroborate our research. We are satisfied that the facts and the evidence-based findings of our report accurately reflect the work of Randox during the Covid-19 emergency.”
A spokesman for Randox said:
“We believe this report delivers clear evidence of the performance, outcomes and value of the work which Randox is proud to have carried out during one of the greatest peacetime emergencies to have hit the world and the UK.
Editors Notes
Gareth Hagan is interview for media interview
OCO Global is a leading specialist provider of trade and investment services. Headquartered in Northern Ireland, OCO Global has offices in the UK, Ireland, Germany, France, Japan, UAE, China and the U.S.
OCO Global’s clients include leading national, state and regional economic development organizations such as The Department For International Trade (DIT), Enterprise Florida and The Japan External Trade Organization (JETRO), as well as private companies seeking to enter new markets or grow their domestic base, including EY, PWC, Siemens, Smiley Monroe, Pepsico and Santander.
Media Enquiries to Ian Monk /Heather Vernon
Ian.monk@woburnpartners.com +44 7970 026072
Heather.vernon@woburnpartners.com +44 7747 097821
Randox in the media
Latest News
FAQs
Open Day at Randox Teoranta!
We are hosting an open day at Randox Teoranta!
We are delighted to invite you to our careers open day at Randox Teoranta, which will take place on Saturday 8th April from 9.30am to 12.30pm.
This is a fantastic opportunity to discover more about our innovative medical diagnostic technologies and products, as well as to learn about the exciting career opportunities available within our state-of-the-art facility located in Dungloe, Co. Donegal, F94 TV06.
We are Recruiting for these exciting opportunities:
– Engineering Roles
– Scientific Roles
– Manufacturing Roles
– Admin/Support Roles
Come in and see the facility and discuss job opportunities directly with staff. Tea, coffee and traybakes will be available in the morning as well as the chance to win our Easter basket!
Why work at Randox Teoranta?
At Randox Teoranta, we take great pride in fostering a strong company culture that emphasises teamwork, collaboration, and support. We believe that our success is due in large part to the dedicated and motivated individuals who make up our team. Our employees aren’t just colleagues, they’re part of our family. We encourage open communication, provide opportunities for personal and professional growth, and celebrate the achievements of our team members.
Company Culture
Learning Opportunities
At Randox, we offer extensive opportunities for learning and development in various fields such as business, science, design, technology, and engineering. Our fast-paced and forward-thinking work culture values fresh and innovative ideas that can ultimately transform healthcare and save lives.
Whether you’re a full-time employee or a student, Randox Laboratories is a great place to grow and advance in your career. Our highly active placement programs for 1st and 2nd year students in every sector provide 50+ positions each year!
Worldlab∙Euromedlab 2023
We will be exhibiting at Worldlab∙Euromedlab 2023!
We invite you to stop by RCC La Nuvola in Rome between May 21st and May 25th, 2023 for a visit.
Make sure to drop by Booth #153, where we’ll be engaging in conversations about cutting-edge diagnostic products and solutions, while also showcasing our groundbreaking technologies.
With over four decades of experience in the medical diagnostics industry, Randox is dedicated to enhancing global health outcomes. As a provider of high-quality diagnostic solutions, Randox offers a wide range of products and services, including Quality Control, Molecular Diagnostics, Third Party Reagents, Point of Care, and Clinical Chemistry Analysers.
Meet The Team
If you plan to attend Worldlab∙Euromedlab 23, our Product Specialists Team will be available at Booth #153 to answer any questions you may have. To ensure the most productive use of your time, we recommend scheduling a meeting with one of our Randox representatives in advance to discuss your specific needs and book a time slot during the five-day event by clicking on the button below:
Randox Supports Family Business Week 21st-25th November 2022
Randox Supports Family Business Week 21st-25th November 2022
The theme for Family Business Week 2022 is ‘Celebrating Our Place in the World’. It will highlight the central role family firms play in shaping and supporting their local communities, economy and natural environment. The campaign is led by the IFB, the voice of the UK’s family business sector and supported by NatWest.
In honour of this week, Randox would like to share our family business history:
In April 1982, Randox Laboratories was founded by Dr Peter Fitzgerald from a converted chicken house off Randox Road, near Crumlin in Antrim, where he had grown up.
FitzGerald started out using equipment discarded by university research labs but, through decades of hard work and innovation, slowly built the company into a market leader. Randox Laboratories is now the largest diagnostics company from the UK with over 40 years of experience operating in over 145 countries.
The Covid-19 pandemic saw Randox Laboratories on the front line for testing for the Covid-19 virus across the UK and Ireland. After downloading the virus genetic sequence in January 2020, Randox were able to quickly develop a test. This meant that by March 2020, Randox were provided with a contract by Public Health England to test as part of the National Testing Program.
After investing in 78,000 sq ft of laboratory testing space and hiring additional staff, Randox were able to process over 25million PCR tests as part of the National Testing Program as well as private testing allowing a return to work and travel.
Expanding into the travel market and providing an essential service to people to travel to see loved ones after years in isolation. There was a realisation that the future landscape for healthcare has changed forever. People have become used to testing themselves. People want to know the status of their health and are actively taking control of their health and wellbeing.
Randox Health has recently made significant investment to deliver our preventative, personalised testing packages across the nation and are opening up to 25 Randox Health clinics in the short term – In England, Ireland, Scotland, and Wales. Randox Health clinics focus on the provision of cost-effective, timely and accurate testing to identify risk to health, improve clinical diagnoses and promote preventative healthcare. Our aim is to improve and save lives through early detection of disease.
The growing network of clinics provide easy access for millions of people to a new Randox range of diagnostic tests, including for cancer, vitamin deficiencies, hormone imbalances, allergies and key health concerns including heart, liver, and kidney conditions. Real time insights on current and future health risks are provided to empower clients to make simple dietary and lifestyle changes giving them the power to extend their lives.
Randox clinics also offer a new range of comprehensive diagnostic programmes, including the ‘EveryMan’ and ‘EveryWoman’ 12-month programmes/full body ‘MOTs’. These enable up to 150 data points linked to key health areas to be measured during each visit with a personalised health plan summarising results provided. Repeat tests and consultation will be arranged six months after the initial test, included in the testing programme prices, which start at £295 per person.
Randox Win IT Team or Department of the Year at the 2022 Belfast Telegraph IT Awards
Randox would like to congratulate the IT Department on their Belfast Telegraph IT Awards Win!
The Randox IT department were delighted to win the IT Team or Department of the Year award sponsored by Continu. Described as the ‘clear winner’ by Belfast Telegraph, Randox IT won the award due to their hard work and dedication during the Covid-19 pandemic.
The awards took place on Friday at the MAC Theatre in Belfast and was hosted by comedian Neil Delamere. Northern Ireland’s incredible IT industry was showcased displaying their great achievements and their significant, positive impact on the local economy.
In the past 12 months, Randox IT department transformed the cutting-edge systems and facilities created during the pandemic to allow customers to take control of their health through preventative testing. Randox IT were very much at the forefront of innovation and continued to develop and enhance our offerings, processing 27 million covid results in total. Furthermore, expanding into the travel market and providing an essential service to people who could finally travel to see loved ones after years in isolation.
The team’s disruptive approach to development has allowed Randox to respond quickly in an ever-evolving situation and introduce a full end-to-end testing process facilitating multiple key stages such as, logistics, registration, accessioning, sample processing and results reporting.
At the beginning of 2022, there was a realization that the future landscape for healthcare has changed forever. People want to know the status of their health and are actively taking control of their health and wellbeing. Through these innovate solutions developed by Randox IT in the fight against covid, the team have focused on the future vision of healthcare and developed solutions for customers to test themselves, in clinic or at home, for areas such as heart health, Thyroid health, STI, Vit and Minerals as well as our most popular packages of Everyman, Everywomen, Signature, Every Athlete.
This has only been possible due to the dedication and expertise of the IT team who released a new version of the Randox Health customer platform, which provides each customer with a customized view of their health. Customers have key insights to their health data allowing them to track their health.
Randox would like to Congratulate Eileen Nixon on her Retirement
Randox would like to congratulate Eileen Nixon on her retirement!
Eileen has been a valuable member of Randox for 32 years beginning her career here in November 1990. She describes how remarkable the growth of Randox has been. From a smaller scale business back in 1990 to now the largest diagnostics company from the UK.
On Thursday morning, we celebrated Eileen’s achievements and fond memories during her time in our Manufacturing Division, within the Packing Team. The room was filled with Eileen’s colleagues, many of whom had worked with Eileen for well over 20 years. Eileen has been a great member of the Randox team and will be sorely missed.
We wish Eileen good health and every happiness for her retirement.
ABOUT RANDOX
NEWS
VACANCIES
OUR PEOPLE
Randox collaborate with Verv Technologies to Improve Health for All
Randox Laboratories, the largest diagnostics company from the UK, are proud to announce a $3.8m CAD seed round with Verv Technologies.
Randox Laboratories are the lead investor for Verv Technologies, who are focused on creating the first of its kind consumer-oriented, affordable, high-quality blood chemistry analyser with disposable tests for home use, that will help individuals measure a wide range of analytes (i.e., cholesterol, vitamin levels, hormones). With over 40 years of diagnostic experience, Randox Laboratories are focused on investment into technologies to improve health for all.
Dr. Peter Fitzgerald, Managing Director of Randox Laboratories shared, “Randox has a global lens on the development of new technologies. We have a shared vision and belief in Verv’s unique, highly differentiated microfluidics approach to creating scalable, high-quality, low-cost blood testing technology for healthcare consumers. We anticipate a great journey ahead, in partnership with Verv.
Jeff Sutton, Founder and President of Verv Technologies describes, “We are thrilled to have Randox as a major investor in Verv to help propel us to commercial readiness and the opportunity to work with the original Founder and Managing Director of Randox, Dr. Peter Fitzgerald, who will join Verv’s Board of Directors. We aim to create great value for health-conscious consumers.”
Randox and Verve share a commitment to transform testing on a global scale for the benefit of healthcare consumers.